Cardiovascular Disease Screening
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will evaluate volunteers 18 years of age and older to see if they qualify for one of NHLBI's research studies. Tests include the following:
- General medical evaluation, which may include blood tests, chest x-ray, electrocardiogram (ECG) and echocardiogram (heart ultrasound).
- Other tests as appropriate, such as magnetic resonance imaging (MRI), cardiac computed tomography (CT scan of the heart), nuclear stress test and echocardiography stress test.
- X-ray contrast studies of the heart and blood vessels. (These may be excluded in patients with kidney risk factors.)
| Condition |
|---|
|
Congenital Heart Disease Atherosclerosis Myocardial Ischemia Myocardial Infarction Acquired Heart Disease |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Suburban/NHLBI Cardiovascular Disease Screening Protocol |
| Study Start Date: | June 2007 |
This is a screening protocol. This protocol allows two functions: 1) the protocol allows physicians in the Suburban/NHLBI Cardiovascular Imaging program to evaluate patients referred to the program with clinically indicated studies and research studies. 2) It is also designed to determine if patients may be suitable candidates for one of our NHLBI research protocols.
Patients greater than or equal to 18 years of age referred for possible cardiovascular disease will be enrolled in the protocol for a period of one year. At one year, patients will either be: 1) transferred to one of our specific research MRI or CT protocols, 2) removed from the screening protocol and made inactive, or 3) re-enrolled on the screening protocol with the patient's consent.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
- ELIGIBILITY CRITERIA:
No one will be excluded from this study based on race, gender, or ethnicity.
A. General Inclusion Criteria:
- Age greater than or equal to 18
- Capable of giving informed consent.
B. General Exclusion Criteria (for all arms):
- Pregnant women (uncertain patients will have urine or blood testing).
- Decompensated heart failure (unable to lie flat in bed).
Test Specific Exclusion Criteria:
A. CT Exclusion Criteria (excludes contrast enhanced CT scan only):
- Allergy to iodinated contrast agent excludes contrast enhanced CT research studies.
- Multiple myeloma.
- Patients with severe kidney disease (eGFR less than 30 mL/min/1.73 m(2).
B. Beta Antagonist Exclusions (excluded the use of beta blocker only):
- Asthma or severe chronic lung disease/emphysema with regular use of inhaler.
- Decompensated heart failure.
C. MRI Exclusion Criteria (excludes MRI scan only):
- Cardiac pacemaker or implantable defibrillator.
- Cerebral aneurysm clip.
- Neural stimulator (e.g. TENS-Unit).
- Any type of ear implant.
- Metal in eye (e.g. from machining).
- Any implanted device (e.g. insulin pump, drug infusion device).
D. Exclusions from MRI contrast agents:
- Lactating women unless they are willing to discard breast milk for 24 hours.
- Severe kidney disease (less than 30 mL/min/1.73 m(2).
E. Vasodilator Exclusions (excludes some vasodilator stress testing):
- Asthma or chronic obstructive pulmonary disease (emphysema) actively treated with bronchodilators or leukotriene receptor antagonists (albuterol, seravent, atrovent, montelukast singulair, zafirlukast Accolate. These conditions only exclude adenosine and dipyridamole.
- Second degree (Type II) and third degree atrioventricular heart block.
F. Exclusions from Dobutamine stress MRI only:
- Severe problems with heart rhythms.
- Severe high blood pressure.
G. Exclusion criteria for atropine (given during dobutamine stress echocardiography when target heart rate not achievable with dobutamine alone).
- Narrow angle glaucoma.
- Known or suspected severe bladder outlet obstruction due to prostatic hypertrophy.
Contacts and Locations| Contact: Marsha Block, R.N. | (301) 496-0211 | blockma@mail.nih.gov |
| Contact: Andrew E Arai, M.D. | (301) 496-3658 | araia@nih.gov |
| United States, Maryland | |
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
| Bethesda, Maryland, United States, 20892 | |
| Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 prpl@mail.cc.nih.gov | |
| Suburban Hospital | Recruiting |
| Bethesda, Maryland, United States, 20814 | |
| Principal Investigator: | Andrew E Arai, M.D. | National Heart, Lung, and Blood Institute (NHLBI) |
More Information
Additional Information:
Publications:
| ClinicalTrials.gov Identifier: | NCT00483951 History of Changes |
| Other Study ID Numbers: | 070157, 07-H-0157 |
| Study First Received: | June 7, 2007 |
| Last Updated: | May 1, 2013 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Institutes of Health Clinical Center (CC):
|
Myocardial Infarction Myocardial Ischemia Atherosclerosis Congenital Heart Disease |
Valvular Heart Disease Heart Disease Cardiovascular Disease Heart Valve Disease |
Additional relevant MeSH terms:
|
Atherosclerosis Cardiovascular Diseases Myocardial Ischemia Coronary Artery Disease Heart Diseases Infarction Ischemia Myocardial Infarction Heart Defects, Congenital |
Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Coronary Disease Pathologic Processes Necrosis Cardiovascular Abnormalities Congenital Abnormalities |
ClinicalTrials.gov processed this record on May 22, 2013